Stem Cell Transplant Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Stem Cell Transplant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Phase 1Phase 2

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell Transplantation
National Cancer Institute (NCI)260 enrolled2 locationsNCT05436418
Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled3 locationsNCT06707493
Recruiting
Phase 3

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

B-ALLMRD-positiveAllogenetic Hematopoietic Stem Cell Transplantation
Peking University People's Hospital70 enrolled1 locationNCT07441291
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Not Applicable

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Multiple MyelomaStem Cell Transplant Complications
Dana-Farber Cancer Institute30 enrolled2 locationsNCT05706766
Recruiting
Phase 1Phase 2

A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

Acute Leukemia, High RiskMyelodysplastic Syndromes, High RiskHematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
Ciusss de L'Est de l'Île de Montréal7 enrolled1 locationNCT07301866
Recruiting
Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Not Applicable

Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

NeuroblastomaDelayed Platelet EngraftmentAutologous Hematopoietic Stem Cell Transplantation
Beijing Children's Hospital30 enrolled1 locationNCT06818916
Recruiting
Phase 2

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL

ALLMRD-positiveHematopoietic Stem Cell Transplantation
Sheng-Li Xue, MD42 enrolled1 locationNCT05940961
Recruiting
Phase 1

IS-free Treg HaploHCT

Myelodysplastic SyndromesStem Cell Transplant ComplicationsGraft vs Host Disease+2 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04678401
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Multiple MyelomaMyelodysplastic SyndromeLymphoma+12 more
Yigeng Cao,MD,PhD1,000 enrolled1 locationNCT07205523
Recruiting
Phase 2

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Multiple MyelomaPost Stem Cell Transplant
Stanford University20 enrolled1 locationNCT06461988
Recruiting
Phase 4

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Chinese PLA General Hospital200 enrolled1 locationNCT07101588
Recruiting
Phase 2

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT07101497
Recruiting
Not Applicable

Mosaic Trial for Stem Cell Transplant Recipients

Multiple MyelomaLymphomaLeukemia+4 more
Northwestern University356 enrolled3 locationsNCT06960993
Recruiting
Phase 2

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin LymphomaAutologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota28 enrolled1 locationNCT06377540
Recruiting
Phase 2

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Myelodysplastic SyndromeDiffuse Large B-Cell Lymphoma (DLBCL)Acute Myeloid Leukaemia+2 more
Vastra Gotaland Region100 enrolled5 locationsNCT06793410
Recruiting
Phase 2

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

RelapseT-cell Acute Lymphoblastic LeukemiaALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine59 enrolled1 locationNCT06686108